Labcorp Expands Collaboration with Ultima Genomics to Advance Whole Genome Sequencing Applications and Oncology Testing Capabilities
Labcorp (NYSE: LH) has expanded its collaboration with Ultima Genomics to advance whole genome sequencing (WGS) applications and oncology testing capabilities. The partnership will utilize Ultima's UG 100™ sequencing solution and ppmSeq™ technology to explore new clinical applications, including molecular residual disease (MRD) detection in early-stage solid tumor cancers.
Labcorp recently introduced Labcorp® Plasma Detect™, a WGS-based circulating tumor DNA MRD solution. Preliminary data suggests that combining Plasma Detect with Ultima's technology could improve sensitivity, specificity, and cost-effectiveness in detecting rare variants at extremely low limits. This collaboration aims to transform oncology testing by increasing efficiency, scalability, and affordability of genetic testing in areas with significant unmet needs.
Labcorp (NYSE: LH) ha ampliato la sua collaborazione con Ultima Genomics per promuovere le applicazioni del sequenziamento genomico completo (WGS) e le capacità di testing oncologico. La partnership utilizzerà la soluzione di sequenziamento UG 100™ di Ultima e la tecnologia ppmSeq™ per esplorare nuove applicazioni cliniche, inclusa la rilevazione della malattia residua molecolare (MRD) nei tumori solidi in fase iniziale.
Labcorp ha recentemente introdotto Labcorp® Plasma Detect™, una soluzione MRD basata su WGS per il DNA tumorale circolante. I dati preliminari suggeriscono che combinando Plasma Detect con la tecnologia di Ultima potrebbe migliorare sensibilità, specificità ed economicità nella rilevazione di rare varianti a limiti estremamente bassi. Questa collaborazione mira a trasformare il testing oncologico aumentando l'efficienza, la scalabilità e l'accessibilità dei test genetici in aree con significative esigenze non soddisfatte.
Labcorp (NYSE: LH) ha ampliado su colaboración con Ultima Genomics para avanzar en las aplicaciones de secuenciación del genoma completo (WGS) y las capacidades de pruebas oncológicas. La asociación utilizará la solución de secuenciación UG 100™ de Ultima y la tecnología ppmSeq™ para explorar nuevas aplicaciones clínicas, incluida la detección de enfermedad residual molecular (MRD) en cánceres sólidos en etapas tempranas.
Labcorp presentó recientemente Labcorp® Plasma Detect™, una solución MRD basada en WGS para el ADN tumoral circulante. Los datos preliminares sugieren que combinar Plasma Detect con la tecnología de Ultima podría mejorar la sensibilidad, la especificidad y la rentabilidad en la detección de variantes raras en límites extremadamente bajos. Esta colaboración tiene como objetivo transformar las pruebas oncológicas aumentando la eficiencia, escalabilidad y asequibilidad de las pruebas genéticas en áreas con necesidades no satisfechas significativas.
Labcorp (NYSE: LH)는 Ultima Genomics와의 협력을 확대하여 전체 유전체 시퀀싱(WGS) 응용 프로그램과 종양학 테스트 기능을 발전시키고 있습니다. 이번 파트너십은 Ultima의 UG 100™ 시퀀싱 솔루션과 ppmSeq™ 기술을 활용하여 초기 고형 종양 암에서의 분자 잔여 질병(MRD) 탐지를 포함한 새로운 임상 응용 프로그램을 탐색할 것입니다.
Labcorp는 최근 Labcorp® Plasma Detect™라는 WGS 기반 순환 종양 DNA MRD 솔루션을 도입했습니다. 초기 데이터는 Plasma Detect와 Ultima의 기술을 결합함으로써 극히 낮은 한계에서 희귀 변종 탐지의 민감도, 특이성 및 비용 효율성을 개선할 수 있음을 시사합니다. 이 협력은 중요한 unmet needs가 있는 지역에서 유전자 테스트의 효율성, 확장성 및 비용 효율성을 높여 종양학 테스트를 변화시키는 것을 목표로 하고 있습니다.
Labcorp (NYSE: LH) a élargi sa collaboration avec Ultima Genomics pour faire avancer les applications de séquençage complet du génome (WGS) et les capacités de test en oncologie. Le partenariat utilisera la solution de séquençage UG 100™ d'Ultima et la technologie ppmSeq™ pour explorer de nouvelles applications cliniques, y compris la détection de maladie résiduelle moléculaire (MRD) dans les cancers solides à un stade précoce.
Labcorp a récemment introduit Labcorp® Plasma Detect™, une solution MRD basée sur WGS pour l'ADN tumoral circulant. Des données préliminaires suggèrent que la combinaison de Plasma Detect avec la technologie d'Ultima pourrait améliorer la sensibilité, la spécificité et le rapport coût-efficacité pour détecter des variantes rares à des limites extrêmement basses. Cette collaboration vise à transformer les tests oncologiques en augmentant l'efficacité, l'évolutivité et l'accessibilité des tests génétiques dans des domaines ayant des besoins non satisfaits significatifs.
Labcorp (NYSE: LH) hat seine Zusammenarbeit mit Ultima Genomics ausgeweitet, um die Anwendungen des gesamten Genomsequenzierens (WGS) und die Testmöglichkeiten in der Onkologie zu verbessern. Die Partnerschaft wird Ultimas UG 100™ Sequenzierungslösung und ppmSeq™ Technologie nutzen, um neue klinische Anwendungen zu erkunden, einschließlich der molekularen Restkrankheit (MRD) bei frühen soliden Tumoren.
Labcorp hat kürzlich Labcorp® Plasma Detect™ eingeführt, eine auf WGS basierende MRD-Lösung für zirkulierende Tumordna. Vorläufige Daten deuten darauf hin, dass die Kombination von Plasma Detect mit Ultimas Technologie die Sensitivität, Spezifität und Kosteneffizienz bei der Detection seltener Varianten in extrem niedrigen Grenzen verbessern könnte. Diese Zusammenarbeit zielt darauf ab, die Onkologie-Tests zu transformieren, indem sie die Effizienz, Skalierbarkeit und Erschwinglichkeit von genetischen Tests in Gebieten mit erheblichen unerfüllten Bedürfnissen erhöht.
- Expansion of collaboration with Ultima Genomics to advance whole genome sequencing capabilities
- Introduction of Labcorp® Plasma Detect™, a clinically validated WGS-based MRD solution
- Potential for improved sensitivity, specificity, and cost-effectiveness in rare variant detection
- Aims to increase efficiency, scalability, and affordability of genetic testing in oncology
- None.
This collaboration between Labcorp and Ultima Genomics marks a significant advancement in oncology testing, particularly in the realm of whole genome sequencing (WGS) and molecular residual disease (MRD) detection. The integration of Ultima's UG 100™ sequencing solution and ppmSeq™ technology with Labcorp's Plasma Detect™ platform could potentially revolutionize early-stage solid tumor cancer detection and monitoring.
The key advantages of this partnership include:
- Enhanced sensitivity and specificity in detecting rare variants
- Improved efficiency and scalability of testing workflows
- Potential for more cost-effective genetic testing
These advancements could lead to earlier detection of cancer recurrence and more personalized treatment strategies. However, it's important to note that while preliminary data is promising, large-scale clinical validation studies will be necessary to confirm the real-world performance and clinical utility of this combined approach.
For investors, this collaboration could position Labcorp as a frontrunner in the rapidly growing field of precision oncology. The potential for increased test volumes and market share in oncology testing could drive future revenue growth. However, the timeline for full clinical implementation and reimbursement approval remains uncertain, which could impact short-term financial returns.
This expanded collaboration between Labcorp and Ultima Genomics has significant implications for Labcorp's market position and financial outlook. By leveraging Ultima's advanced sequencing technology, Labcorp is poised to enhance its oncology testing capabilities, potentially leading to increased market share and revenue streams.
Key financial considerations include:
- Potential for increased test volumes and higher-margin offerings in oncology diagnostics
- Improved cost-effectiveness of testing, which could enhance profitability
- Possible expansion of Labcorp's client base, including both healthcare providers and biopharmaceutical companies
However, investors should be aware of potential risks:
- Initial capital expenditures required for technology integration
- Uncertain timeline for full clinical implementation and regulatory approvals
- Competitive pressures in the rapidly evolving genomic testing market
While the collaboration's long-term potential is promising, short-term financial impacts may be as the technology undergoes further validation and clinical integration. Investors should monitor Labcorp's R&D expenses and capital expenditures in the coming quarters for indications of the scale of investment in this new technology.
Labcorp recently introduced Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, WGS-based circulating tumor DNA (ctDNA) MRD solution for research and investigational use. Labcorp intends to use Ultima's UG 100 platform and ppmSeq technology, which, combined with Plasma Detect, have demonstrated in preliminary data the ability to detect rare variants at extremely low limits, improved sensitivity and specificity, and more efficient, scalable and cost-effective workflows.
"By combining Labcorp's leadership, testing capabilities and expansive network with the accuracy, scalability and cost-effectiveness of Ultima's technology, we can help transform oncology testing for pathologists, oncologists and our biopharmaceutical partners," said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president, medical lead for oncology at Labcorp. "Through this collaboration, Labcorp aims to drive increased efficiency, scalability and cost-effectiveness while improving access to affordable genetic testing in emerging areas with significant unmet need."
"We look forward to expanding our collaboration with Labcorp to explore the use of our technology in the fast-growing clinical areas of MRD and clinical WGS," said Gilad Almogy, CEO of Ultima Genomics. "At Ultima, we developed our unique sequencing architecture to specifically meet the needs of large-scale applications. The ability to be accurate at extremely low limits of detection with our ppmSeq technology and extreme sequencing depth will be transformational for oncology testing and applications such as cell-free DNA."
This relationship follows other strategic collaborations Labcorp has established to improve patient and provider access to and affordability for innovative technologies.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for
About Ultima Genomics
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-expands-collaboration-with-ultima-genomics-to-advance-whole-genome-sequencing-applications-and-oncology-testing-capabilities-302209091.html
SOURCE Labcorp
FAQ
What is the purpose of Labcorp's expanded collaboration with Ultima Genomics?
What technologies are being used in the Labcorp (LH) and Ultima Genomics collaboration?
How might this collaboration impact oncology testing for Labcorp (LH)?
What is Labcorp® Plasma Detect™ and how does it relate to the collaboration with Ultima Genomics?
